Controversial advertising of medicines. A comparison between Poland and the United States

Marta Makowska

doi:10.18778/1899-2226.21.5.06

Autor

Marta Makowska Warsaw University of Life Sciences, Faculty of Social Sciences, Department of Sociology

DOI:

https://doi.org/10.18778/1899-2226.21.5.06

Słowa kluczowe:

pharmaceutical industry, advertisement, drugs, law, ethics

Abstrakt

For many years, the subject of aggressive marketing campaigns conducted by pharmaceutical companies has been raised in Poland. Drug ads are everywhere, on television, the radio, magazines and on the Internet. Therefore, it is extremely important is to ensure both their legal and ethical dimension. This article will present the differences between direct-to-consumer advertising of medicines in Poland and in the US. The dissimilarities result mainly from differences in legislation. In Poland, the law is much stricter than in the US. For example, in the United States companies are allowed to advertise prescription drugs directly to patients. In the whole of the European Union, and thus in Poland, it is strictly prohibited. The article will also present other regulations existing in Poland and in the United States and it will compare them. It will offer examples of violations of the law and ethics in the advertising of medicine in both countries. Lastly, it will briefly outline the negative consequences of unacceptable pharmaceutical marketing.

Bibliografia

Arnold, D., & Oakley, J. (2013). The politics and strategy of industry selfregulation: The pharmaceutical industry’s principles for ethical Direct-to-Consumer advertising as a deceptive blocking strategy. Journal of Health Politics, Policy and Law, 38(3), 505–544.

ASRC. (2012). NARB Panel Recommends Novartis Discontinue Claims that Excedrin Starts Relieving Headache Pain Faster than Advil Claims at Issue Challenged by Pfizer Consumer Healthcare. http://www.asrcreviews.org/2012/01/narb-panel-recommends-novartis-discontinue-claims-that-excedrin-starts-relieving-headache-pain-faster-than-advil-claims-at-issue-challengedby-pfizer-consumer-healthcare/

Blinkoff, S., & Tabela, K. (2015). USA – pharmaceutical advertising 2015. International comparative legal guides. http://www.iclg.co.uk/practice-areas/pharmaceutical-advertising/pharmaceutical-advertising-2015/usa

Chaniecka, K. A., & Czerw, A. (2013). Płeć a postrzeganie reklamy telewizyjnej leków OTC. Hygeia Public Health, 48, 509–514.

Chief Pharmaceutical Inspectorate. (2011, January 31). Decision of 31.01.2011, sign: GIF-P-R-450/106-4/JD/10/11. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/80,Rok-2011.html

Chief Pharmaceutical Inspectorate. (2012, April 26). Decision of 26.04.2012, sign: GIF-P-R-450/14-2/JD/12,2012. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/archiwum/wstrzymanie-reklam/79,Rok-2012.html

Chief Pharmaceutical Inspectorate. (2014, September 9). Decision of 11.09.2014, sign: GIF-P-R-450/46-2/JD/14. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje/619,Decyzja-z-dnia-11092014-znak-GIF-P-R-45046-2JD14.html.

Chief Pharmaceutical Inspectorate. (n.d.) Decisions and messages. https://www.gif.gov.pl/pl/decyzje-i-komunikaty/decyzje/decyzje

Committee of Advertising Ethics [Rada Reklamy]. (2011). Uchwała Nr ZO 40/11 w sprawie reklamy firmy Novartis Poland Sp. z o.o. [Resolution No. ZO40/11 regarding the advertising of Novartis Poland Sp. z o.o.].https://www.radareklamy.pl/uchwaly-ker/2011/uchwa%C5%82a-nr-zo-40-11 -w-sprawie-reklamy-firmy-novartis-poland-sp-z-o-o

Committee of Advertising Ethics [Rada Reklamy]. (2014). Uchwała Nr ZO 64/14 w sprawie reklamy firmy Pfizer Trading Polska Sp. z o.o. [Resolution No.ZO 64/14 regarding the advertising of Pfizer Trading Polska Sp. z o.o.].https://www.radareklamy.pl/uchwaly-ker/2014/uchwa%C5%82a-nr-zo-64-14-w-sprawie-reklamy-firmy-pfizer-trading-polska-sp-z-o-o

Committee of Advertising Ethics [Rada Reklamy]. Commission of Ethics [Komisja Etyki Reklamy]. https://www.radareklamy.pl/komisja-etyki-reklamy

Consumer Healthcare Products Association. (2015). OTC Drug Advertising. http://www.chpa.org/OTCDrugAdvertising.aspx

Diehl, S., Mueller, B., & Terlutter, R. (2008). Consumer responses towards nonprescription and prescription drug advertising in the US and Germany: They don’t really like it, but they do believe it. International Journal of Advertising, 27(1), 99–131.

Donohue, J. (2006). A history of drug advertising: The evolving roles of consumers and consumer protection. Milbank Quarterly, 84, 659–699.

Faerber, A. E., & Kreling, D. H. (2012). Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. Journal of General Internal Medicine, 29(1), 110–118.

Food and Drugs Administration. (2014a). Cipher Pharmaceuticals Inc. Warning Letter. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ UCM415228.pdf

Food and Drugs Administration. (2014b). Pacira Pharmaceuticals, Inc. Warning Letter. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM416514.pdf

Food and Drugs Administration. (2015a). Drug Applications for Over-the-Counter (OTC) Drugs. https://www.fda.gov/drugs/developmentapprovaprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htm

Food and Drugs Administration. (2015b). Inspections, Compliance, Enforcement, and Criminal Investigations, Warrning Letters, Drugs. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/default.htm

Food and Drugs Administration. (n.d.). Prescription Drug Advertising. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/default.htm

Frosch, D., Kruger, P. M., Hornik, R. C., Cronholm, P., & Barg, F. (2007). Creating demand for prescription drugs: A content analysis of television Directto-Consumer advertising. Annals of Family Medicine, 1(5), 6–13.

Journal of Laws of the Republic of Poland 1991, No. 105, position 452. Act on pharmaceuticals, medical materials, pharmacies, wholesalers and pharmaceutical supervision. [Dz.U. 1991, No. 105, item 452, Ustawao środkach farmaceutycznych, materiałach medycznych, aptekach, hurtowniach i nadzorze farmaceutycznym].

Journal of Laws of the Republic of Poland 1993, No. 47, position 211. The Act on Combating Unfair Competition. [Dz.U. 1993, No. 47, item 211, Ustawa ozwalczaniu nieuczciwej konkurencji].

Journal of Laws of the Republic of Poland 2008, No. 45, position 271. Pharmaceutical Law. [Dz.U. 2008, No. 45, item 271, Prawo Farmaceutyczne].

Koncerny farmaceutyczne mocno inwestują w reklamę. Aflofarm na czele peletonu. (2014). www.marketingprzykawie.pl. http://www.marketingnews.pl/ theme.php?art=1804.

KPMG & IAA. (2015). Rynek reklamy telewizyjnej w Polsce po latach wychodzi na prostą. Warsaw.

Kravitz, R. L. (2000). Direct-to-Consumer advertising of prescription drugs. Western Journal of Medicine, 173(4), 221–222.

Kula, P. (2015). Pharmaexpert podsumowuje rynek apteczny w 2014 roku. http://www.aptekarzpolski.pl/2015/02/01-2015-pharmaexpert-podsumowuje-rynek-apteczny-w-roku-2014/

Mack, J. (2015). Increased DTC advertising and rising drug prices – Is there a causal link? http://pharmamkting.blogspot.com/2015/11/increased-dtc-advertising-and-rising.html

Makowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.

Makowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.

Michalski, B., Sławatyniec, Ł., Duczyńska, M., & Kęska, K. (2013). Prawo farmaceutyczne i refundacja leków. Warszawa: Wolters Kluwer.

Mogull, S. A. (2008). Chronology of Direct-to-Customer advertising regulation in the United States. American Medical Writers Association Journal, 23(3), 106–109.

PAIiIZ. (2013). Sektor faramaceutyczny i biotechnologiczny w Polsce. Warszawa: The Polish Investment and Trade Agency.

Stange, K. C. (2007). Time to ban Direct-to-Consumer prescription drug marketing. Annals of Family Medicine, 5(2), 101–104.

Sudak, I. (2015, March 4). My, Polacy, lekomani. Rekordowe wydatki na leki, groźne skutki reklam. Gazeta Wyborcza. http://wyborcza.biz/biznes/1,100896,17513743,My__Polacy__lekomani__Rekordowe_wydatki_na_leki__grozne.html#ixzz3uwzWsiDa

Szuba, T. (1994). Polityka leku w Polsce. Aptekarz, 2(9), 379–386.

Szuba, T. (2003). Ekonomka leku. Podręcznik dla studentów farmacji i farmaceutów. Aptekarz, 11(10), 257–292.

Ventola, C. (2011). Direct-to-Consumer pharmaceutical advertising. Therapeutic or toxic? Pharmacy and Therapeutics, 10(36), 669–684.

Zarzeczna-Baran, M., Bandurska, E., Pęgiel-Kamrat, J., & Lewandowska, A. (2013). The impact of advertising on purchase of OTC drugs. Annales Academiae Medicae Gedanensis, 43, 77–87.